Viridian Therapeutics, Inc./DE
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-342.6M | $-269.9M | $-237.7M | $-129.9M | $-79.4M | $-110.7M | $-41.9M | $-32.7M |
| Depreciation & Amortization | $460.0K | $540.0K | $522.0K | $255.0K | $120.0K | $239.0K | $288.0K | $281.0K |
| Depreciation | — | — | — | — | — | — | — | — |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $44.3M | $42.2M | $67.2M | $19.8M | $14.5M | $3.6M | $4.0M | $3.7M |
| Net Cash from Operating Activities | $-276.4M | $-232.3M | $-184.2M | $-93.8M | $-54.6M | $-29.8M | $-36.1M | $-26.8M |
| Investing Activities | ||||||||
| Capital Expenditures | $495.0K | $511.0K | $898.0K | $797.0K | $338.0K | $42.0K | $84.0K | $445.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-37.6M | $-228.7M | $-94.3M | $-115.1M | $-74.3M | $-50.5M | $28.2M | $-29.9M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $426.7M | $457.7M | $225.7M | $322.2M | $125.3M | $101.3M | $70.0K | $41.9M |
| Net Change in Cash | $112.8M | $-3.2M | $-52.8M | $113.3M | $-3.6M | $21.1M | $-7.8M | $-14.8M |
| Free Cash Flow | $-276.9M | $-232.8M | $-185.1M | $-94.6M | $-54.9M | $-29.8M | $-36.1M | $-27.3M |